A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma

Cancer

Volumn 117, Issue 18, 2011, Pages 4194-4200

  Harzstark, Andrea L ^a   Small, Eric J ^a   Weinberg, Vivian K ^b   Sun, Janine ^a   Ryan, Charles J ^a   Lin, Amy M ^a   Fong, Lawrence ^a   Brocks, Dion R ^c   Rosenberg, Jonathan E ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

clear cell; combination therapy; everolimus; mammalian target of rapamycin (mTOR) inhibitor; renal cell carcinoma; sorafenib; tyrosine kinase inhibitor

Indexed keywords

ALLOPURINOL; ANTICOAGULANT AGENT; BEVACIZUMAB; CISPLATIN; COLCHICINE; EVEROLIMUS; GEMCITABINE; INFUSION FLUID; INTERFERON; INTERLEUKIN 2; NONSTEROID ANTIINFLAMMATORY AGENT; SORAFENIB; WARFARIN;

ADULT; AGED; ANAL MUCOSITIS; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CHEMOTHERAPY INDUCED EMESIS; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; GILBERT DISEASE; GOUT; HAND FOOT SYNDROME; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATASIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG TOXICITY; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PHOTOSENSITIVITY; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RECOMMENDED DRUG DOSE; SIDE EFFECT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSITIONAL CELL CARCINOMA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINES; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 80052428136     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25931     Document Type: Article

References (12)

1. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008; 26: 5422-5428.
2. Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010; 28: 2144-2150.
3. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-134. (Pubitemid 46089673)
4. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124. (Pubitemid 46089672)
5. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28: 1061-1068.
6. Brenner W, Farber G, Herget T, Lehr HA, Hengstler JG, Thuroff JW., Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer. 2002; 99: 53-57. (Pubitemid 34273197)
7. Kwon YS, Hong HS, Kim JC, Shin JS, Son Y., Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest Ophthalmol Vis Sci. 2005; 46: 454-460. (Pubitemid 40270322)
8. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372: 449-456.
9. O'Reilly T, Wood JM, Littlewood-Evans A, et al. Differential anti-vascular effects of mTOR or VEGFR pathway inhibition: a rational basis for combining RAD001 and PTK787/ZK222584. Proc Am Assoc Cancer Res. 2005; 46: 3038.
10. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
11. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J., Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17: 2530-2540. (Pubitemid 29368255)
12. Boulay A, Zumstein-Mecker S, Stephan C, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. 2004; 64: 252-261. (Pubitemid 38114106)